- Product NameDoravirine
- Brief DescriptionInhibitors
- Purification98.00%
- Biological ActivityDoravirine, also known as MK-1439, is a non-nucleoside reverse transcriptase inhibitor under development by Merck & Co. for use in the treatment of HIV/AIDS. MK-1439 is a novel NNRTI with a 50% inhibitory concentration (IC50) of 12, 9.7, and 9.7 nM against the wild type (WT) and K103N and Y181C reverse transcriptase (RT) mutants, respectively. MK-1439 showed excellent potency in suppressing the replication of WT virus, with a 95% effective concentration (EC95) of 20 nM, as well as K103N, Y181C, and K103N/Y181C mutant viruses with EC95 of 43, 27, and 55 nM, respectively. MK-1439 exhibited similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses).
- Target NameHIV Protease inhibitor
- CAS No. 1338225-97-0
- Calculated MW 425.75
- Formulation C17H11ClF3N5O3
- Storage 3 years -20˚C powder;2 years -80˚C in solvent;
